Home » Healthcare » Pharmaceuticals » Cancer Biomarkers Market

Cancer Biomarkers Market By Type (Genetic Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Proteomic Biomarkers), By Type of Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer), By Type of Profiling Technologies (Immunoassays, Omics Technologies, Cytogenetics, Imaging Technologies, Bioinformatics), By Application (Diagnostics, Drug Discovery & Development, Prognostics, Risk Assessment) – Growth, Future Prospects, and Competitive Analysis, 2017-2025

Summary
Table Of Content

Market Insights

The report titled “Cancer Biomarkers Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall cancer biomarkers market, along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on the type of cancer, type of profiling technologies, type of application, and different geographies. Biomarkers have many potential applications in oncology, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of the progression of the disease. Factors such as the rising prevalence of cancer, increasing support from government and non-government organizations for cancer biomarker research, an aging population, and the increasing use of biomarkers in the drug discovery and development process

For the purpose of this study, the global cancer biomarker market is segmented on the basis of type into genetic biomarkers, epigenetic biomarkers, metabolic biomarkers, proteomic biomarkers, and others. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

On the basis of types of cancer, such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, etc. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The global cancer biomarker market is also segmented on the basis of the type of profiling technologies used, such as immunoassays, omics technologies, cytogenetics, imaging technologies, and bioinformatics. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The global cancer biomarker market is segmented on the basis of the type of application, such as diagnostics, drug discovery and development, prognostics, risk assessment, and others. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The geographical segmentation of the cancer biomarkers market comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. The market size and forecast for these segments during 2015–2025 and their CAGRs for the period 2017–2025 are provided in this report.

The cancer biomarkers market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Abbott Laboratories, Affymetrix, Inc., DiagnoCure, Inc., Qiagen NV, Illumina, Inc., Roche Diagnostics Ltd., Quest Diagnostics Inc., Agilent Technologies, Inc., Merck & Co., Inc., Hologic, Inc., and Becton Dickinson and Company, among others.

Based on type, the global cancer biomarkers market is segmented as follows:

Genetic Biomarkers
Epigenetic Biomarkers
Metabolic Biomarkers
Proteomic Biomarkers
Other Biomarkers

In 2016, proteomic biomarkers dominated the market by type due to the exceptional market potential of protein biomarkers in diagnostics, prognostics, cancer detection, and other clinical and therapeutic applications. In addition, the increasing focus of pharmaceutical and biotechnology companies on research and development of protein biomarkers is expected to fuel overall market growth. During the forecast period of 2017–2025, epigenetics was observed as the fastest-growing segment as it gained high acceptance in the cancer diagnostics industry. The key factors driving the growth of the epigenetics segment are the high amount of research carried out by many players for the analysis of key epigenetic modifications and the increasing collaboration between diagnostic and pharmaceutical companies for developing precise diagnoses and target-specific treatments.

Based on the type of profiling technologies, the global cancer biomarkers market is segmented as follows:

Immunoassays
Omics Technologies
Cytogenetics
Imaging Technologies
Bioinformatics

Because of key driving factors such as increased adoption of advanced high-throughput technologies in biomarker discovery and development and the rising application of omics-based tests for cancer diagnosis and the drug development process, omics technologies accounted for the largest share of the cancer biomarkers market in 2016 and were also the fastest-growing segment. In addition, incessant developments in high-throughput omics technologies are also backing the growth of this market by expanding the space for prospective biomarkers in cancer research.

Based on the type of cancer, the global cancer biomarkers market is segmented as follows:

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Others

In 2016, breast cancer dominated the cancer biomarkers market by cancer type due to the rising prevalence of the disease, high awareness associated with early diagnosis, increasing public awareness with the assistance of government and non-government organizations, and rising research and development activities in the field of a breast cancer diagnosis. During the forecast period of 2017–2025, lung cancer was observed as the fastest-growing segment due to key driving factors such as the rising prevalence of lung cancer due to an increase in air pollution and frequent smoking observed in the younger generation.

Based on the type of application, the global cancer biomarkers market is segmented as follows:

Diagnostics
Drug Discovery and Development
Prognostics
Risk Assessment
Others

The rising prevalence of cancer, increasing demand for efficient diagnosis techniques against cancer, developing research activities in the field of cancer biomarkers, and increasing awareness associated with an early cancer diagnosis are the key factors driving the overall cancer biomarkers market. In 2016, the applications segment was dominated by diagnostics due to key driving factors such as increasing public awareness about the importance of early diagnosis of cancer and the fact that diagnostic biomarkers enable doctors to decide effective treatment alternatives.

For the purpose of this study, the global cancer biomarkers market is categorized into three segments:

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

In the base year 2016, North America accounted for the largest share in the global cancer biomarkers market due to key driving factors such as the high prevalence of cancer, mounting healthcare expenditure leading to a rise in demand for efficient diagnostic tests and healthcare services, and incessant technological advancements in the cancer biomarkers industry. According to the American Cancer Society, in 2017, about 190,500 cancer deaths in the US were caused by cigarette smoking alone.

An estimated 20% of all cancers diagnosed in the US are caused by a combination of excess body weight, physical inactivity, excess alcohol consumption, and poor nutrition, and thus could also be prevented. During the forecast period of 2017–2025, Asia Pacific was observed as the fastest-growing region in the cancer biomarkers market due to the rising prevalence and awareness of cancer, supportive government policies, market expansion by key market players, and rising application of biomarker tests for cancer diagnosis.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Cancer Biomarkers Market Portraiture
2.1.1. Global Cancer Biomarkers Market, by Type, 2016
2.1.2. Global Cancer Biomarkers Market, by Type of Cancer, 2016
2.1.3. Global Cancer Biomarkers Market, by Profiling Technologies, 2016
2.1.4. Global Cancer Biomarkers Market, by Application, 2016
2.1.5. Global Cancer Biomarkers Market, by Geography, 2016

Chapter 3. Cancer Biomarkers Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Cancer: Epidemiology & Diagnosis Rate
3.3. Cancer Biomarkers: Price Analysis
3.4. Cancer Biomarkers: Future Trends
3.5. Drivers
3.6. Challenges
3.7. Opportunities
3.8. Attractive Investment Proposition, by Geography, 2016
3.9. Major Agreements, Partnerships and Collaborations
3.10. Competitive Landscape
3.10.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
4.1. Overview
4.1.1. Attractive Investment Proposition: Global Cancer Biomarkers Market, by Type
4.2. Genetic Biomarkers
4.3. Epigenetic Biomarkers
4.4. Metabolic Biomarkers
4.5. Proteomic Biomarkers
4.6. Others

Chapter 5. Global Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Cancer Biomarkers Market, by Type of Cancer
5.2. Breast Cancer
5.3. Lung Cancer
5.4. Colorectal Cancer
5.5. Prostate Cancer
5.6. Cervical Cancer
5.7. Others

Chapter 6. Global Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
6.1. Overview
6.1.1. Attractive Investment Proposition: Global Cancer Biomarkers Market, by Type of Profiling Technologies
6.2. Immunoassays
6.3. Omics Technologies
6.4. Cytogenetics
6.5. Imaging Technologies
6.6. Bioinformatics

Chapter 7. Global Cancer Biomarkers Market, by Type of Application, 2015 – 2025 (US$ Mn)
7.1. Overview
7.1.1. Attractive Investment Proposition: Global Cancer Biomarkers Market, by Type of Application
7.2. Diagnostics
7.3. Drug Discovery & Development
7.4. Prognostics
7.5. Risk Assessment
7.6. Others

Chapter 8. Global Cancer Biomarkers Market, by Geography, 2015 – 2025 (US$ Mn)
8.1. Overview
8.2. North America Cancer Biomarkers Market Analysis, 2015 – 2025
8.2.1. North America Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.2.2. North America Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.2.3. North America Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.2.4. North America Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.2.5. North America Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
8.2.5.1. U.S.
8.2.5.2. Canada
8.3. Europe Cancer Biomarkers Market Analysis, 2015 – 2025
8.3.1. Europe Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.3.2. Europe Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.3.3. Europe Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.3.4. Europe Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.3.5. Europe Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
8.3.5.1. U.K.
8.3.5.2. Germany
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. Asia Pacific Cancer Biomarkers Market Analysis, 2015 – 2025
8.4.1. Asia Pacific Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.4.2. Asia Pacific Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.4.3. Asia Pacific Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.4.4. Asia Pacific Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.4.5. Asia Pacific Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
8.4.5.1. Japan
8.4.5.2. China
8.4.5.3. India
8.4.5.4. Rest of APAC
8.5. Latin America Cancer Biomarkers Market Analysis, 2015 – 2025
8.5.1. Latin America Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.5.2. Latin America Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.5.3. Latin America Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.5.4. Latin America Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.5.5. Latin America Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
8.5.5.1. Brazil
8.5.5.2. Mexico
8.5.5.3. Rest of Latin America
8.6. Middle East & Africa (MEA) Cancer Biomarkers Market Analysis, 2015 – 2025
8.6.1. MEA Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.6.2. MEA Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.6.3. MEA Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.6.4. MEA Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.6.5. MEA Cancer Biomarkers Market, by Region, 2015 – 2025 (US$ Mn)
8.6.5.1. UAE
8.6.5.2. Saudi Arabia
8.6.5.3. South Africa
8.6.5.4. Rest of MEA

Chapter 9. Company Profiles
9.1. Abbott Laboratories
9.1.1. Business Description
9.1.2. Financial Information (Subject to data availability)
9.1.3. Product Portfolio
9.1.4. Key Developments
9.2. Affymetrix, Inc.
9.3. Illumina, Inc.
9.4. Qiagen N.V.
9.5. Roche Diagnostics Ltd.
9.6. Agilent Technologies, Inc.
9.7. Quest Diagnostics Inc.
9.8. Merck & Co. Inc.
9.9. Hologic, Inc.
9.10. Becton, Dickinson and Company
9.11. Sino Biological Inc.

List of Figures

FIG. 1 Cancer Biomarkers: Market Segmentation
FIG. 2 Global Cancer Biomarkers Market Share, by Type, 2016 (Value %)
FIG. 3 Global Cancer Biomarkers Market, by Type of Cancer, 2016 (US$ Mn)
FIG. 4 Global Cancer Biomarkers Market Share, by Type of Profiling Technologies, 2016 (Value %)
FIG. 5 Global Cancer Biomarkers Market, by Type of Application, 2016 (US$ Mn)
FIG. 6 Global Cancer Biomarkers Market, by Geography, 2016 (Value %)
FIG. 7 Attractive Investment Proposition, by Geography, 2016
FIG. 8 Market Competition Landscape, by Key Players, 2016
FIG. 9 Global Genetic Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Epigenetic Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Metabolic Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Proteomic Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Other Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Breast Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 15 Global Lung Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 16 Global Colorectal Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 17 Global Prostate Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 18 Global Cervical Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 19 Global Other Cancers Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 20 Global Immunoassays Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 21 Global Omics Technologies Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 22 Global Cytogenetics Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 23 Global Imaging Technologies Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 24 Global Bioinformatics Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 25 Global Diagnostics Application Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 26 Global Drug Discovery & Development Application Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 27 Global Prognostics Application Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 28 Global Risk Assessment Application Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 29 Global Other Applications Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 30 U.S. Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 31 Canada Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 32 U.K. Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 33 Germany Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 34 France Cancer Biomarkers Market, 2015-2025 (US$ Mn)
FIG. 35 Spain Cancer Biomarkers Market, 2015-2025 (US$ Mn)
FIG. 36 Italy Cancer Biomarkers Market, 2015-2025 (US$ Mn)
FIG. 37 Rest of Europe Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 38 Japan Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 39 China Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 40 India Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 41 Rest of Asia Pacific Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 42 Brazil Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 43 Mexico Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 44 Rest of Latin America Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 45 UAE Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 46 Saudi Arabia Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 47 South Africa Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 48 Rest of Middle East and Africa Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 2 Global Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 3 Global Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 4 Global Cancer Biomarkers Market, by Type of Application, 2015 – 2025 (US$ Mn)
TABLE 5 Global Cancer Biomarkers Market, by Type of Geography, 2015 – 2025 (US$ Mn)
TABLE 6 North America Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 7 North America Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 8 North America Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 9 North America Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 10 North America Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Europe Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 12 Europe Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 13 Europe Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 14 Europe Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 15 Europe Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 16 Asia Pacific Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 17 Asia Pacific Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 18 Asia Pacific Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 19 Asia Pacific Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 20 Asia Pacific Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 21 Latin America Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 22 Latin America Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 23 Latin America Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 24 Latin America Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 25 Latin America Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 26 Middle East and Africa Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 27 Middle East and Africa Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 28 Middle East and Africa Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 29 Middle East and Africa Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 30 Middle East and Africa Cancer Biomarkers Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 31 Abbott Laboratories: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Affymetrix, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 33 DiagnoCure Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 34 Qiagen N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 35 Illumina, Inc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 36 Roche Diagnostics Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 37 Quest Diagnostics Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 38 Agilent Technologies Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 39 Merck & Co. Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 40 Hologic, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 41 Becton Dickinson and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 42 Sino Biological Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage

Frequently Asked Questions

What is the size of Cancer Biomarkers Market?

The market for Cancer Biomarkers Market is expected to reach USD 30,284.5 Mn By 2025.

What is the Cancer Biomarkers Market CAGR?

The Cancer Biomarkers Market is expected to see significant CAGR growth over the coming years, at 11.5%.

What is the Forecast period considered for Cancer Biomarkers Market?

The report is forecasted from 2017-2025.

What is the base year considered for Cancer Biomarkers Market?

The base year of this report is 2016.

Who are the major players in this market?

Affymetrix, Inc., DiagnoCure, Inc., Qiagen NV, Illumina, Inc., Roche Diagnostics Ltd., Quest Diagnostics Inc., Agilent Technologies, Inc., Merck & Co., Inc., Hologic, Inc. are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –